

Gender: Female | Birth year: 1975 | WHO: 1

Tumor: Lung adenocarcinoma | Lesions: Liver, Lung | Stage: IV

Clinical summary

Relevant systemic treatment history 6/2023-1/2025 Osimertinib

Recent molecular results

Hartwig WGS (22-Feb-2025)

Biopsy location	Lung (purity 50%)
Molecular tissue of origin prediction	Lung: Non-small cell: LUAD (98%)
Tumor mutational load / burden	TML 160 / TMB 14 mut/Mb
Microsatellite (in)stability	Stable
HR status	Proficient (0)
Driver mutations	EGFR C797S, EGFR L858R, KRAS G12C, KRAS G12D
Amplified genes	None
Deleted genes	TP53 del
Homozygously disrupted genes	None
Gene fusions	MET(exon13)::MET(exon15) fusion
Driver virus	None

Trial-relevant IHC results

PD-L1 Score > 50%

Phase 2/3+ trials in NL that are open and potentially eligible (2 trials)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 04</a> <a href="#">TEDR1</a> (Phase 2)	Lung cancer C797S cohort	EGFR C797S	NKI-AvL	None
<a href="#">EGFR-C797S-TRIAL</a> (Phase 2)	EGFR C797S	EGFR C797S	Elisabeth-TweeSteden Ziekenhuis	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

Phase 1/2 (or unknown phase) trials in NL that are open and potentially eligible (3 trials)

Trial	Cohort	Molecular	Sites	Warnings
<a href="#">METC 02</a> <a href="#">KAYRAS</a> (Phase 1/2)	Dose expansion - monotherapy - NSCLC	KRAS G12D, PD-L1 >= 50.0	Erasmus MC	Variant(s) G12D in KRAS but subclonal likelihood of > 50%
<b>METC 01</b> IEMOEN (Phase 1)	Dose escalation - monotherapy (no slots)	None		Has not exhausted SOC (at least platinum doublet remaining)
<a href="#">EGFR-L858R-TRIAL</a> (Phase 1)	EGFR L858R	EGFR L858R	Elisabeth-TweeSteden Ziekenhuis	

Trials matched solely on molecular event and tumor type (no clinical data used) are shown in italicized, smaller font.

International trials that are open and potentially eligible (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#">KRAS-G12C-TRIAL-DE (Phase 1)</a>	KRAS G12C	KRAS G12C	Germany: Stuttgart

Trials in this table are matched solely on molecular event and tumor type (clinical data excluded).  
1 trial filtered due to trials recruiting nationally for the same molecular target. See Other Trial Matching Results for filtered matches.

Molecular Details

Hartwig WGS (EXAMPLE-LUNG-01-T, 22-Feb-2025)

General

Purity	Ploidy	TML Status	TMB Status	MS Stability	HR Status	DPYD	UGT1A1
50%	2.3	High (160)	High (14)	Stable	Proficient (0)	*1_HOM (Normal function)	*1_HOM (Normal function)

Predicted tumor origin

1. Lung: Non-small cell: LUAD	
Combined prediction score	98%
This score is calculated by combining information on:	
(1) SNV types	60%
(2) SNV genomic localisation distribution	70%
(3) Driver genes and passenger characteristics	80%
Other cohorts have a combined prediction of 2% or lower	

Key drivers

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Mutation (gain of function)	EGFR L858R (2/4 copies)		NCT00000006	Approved	
Mutation (gain of function)	EGFR C797S (1/4 copies)	TEDR1 (NKI-AvL)	NCT00000008	Pre-clinical	
Mutation (gain of function)	KRAS G12D (0.3/2 copies)*	KAYRAS (Erasmus MC)			
Mutation (gain of function)	KRAS G12C (0.3/2 copies)*		NCT00000009		
Deletion	TP53 del				

The table continues on the next page

Continued from the previous page

Type	Driver	Trials (Locations)	Trials in Hartwig	Best evidence in External	Resistance in External
Known fusion	MET(exon13)::MET(exon15) fusion Domain(s) Kept: [Tyrosine Kinase] Domain(s) Lost: [Juxtamembrane]				

\* Variant has > 50% likelihood of being sub-clonal

Other drivers or relevant events

None

IHC results

PD-L1

Score > 50%

Clinical Details

Clinical summary

Relevant systemic treatment history	6/2023-1/2025	Osimertinib
Relevant other oncological history	None	
Previous primary tumor	None	
Relevant non-oncological history	2023	Rheumatoid arthritis

Patient current details (20-Feb-2025)

Unresolved toxicities grade => 2	None
LVEF	50%
Known allergies	None
Recent surgeries	01-Aug-2024 Cholecystectomy

Tumor details (20-Feb-2025)

Measurable disease	Yes
Known lesions	Liver, Lung
No lesions present	CNS, Brain, Bone, Lymph node

Active medication details

Medication	Administration route	Start date	Stop date	Dosage	Frequency
St. John's Wort	Oral	01-Feb-2023		300 MILLIGRAMS	1 / 2 DAYS

Blood transfusions

Product	Date
ERTHROCYTES_FILTERED	20-Sep-2024

Trial Matching Details

Filtered trials potentially eligible based on molecular results which are potentially recruiting (1 trial)

Trial	Cohort	Molecular	Sites
<a href="#">EGFR-BE</a> <a href="#">(Phase 1)</a>	EGFR L858R	EGFR L858R	Belgium: Brussels

Trials and cohorts that are potentially eligible, but are closed (1 trial)

Trial	Cohort	Molecular	Sites	Warnings
<b>METC 01</b> IEMOEN (Phase 1)	Dose expansion - monotherapy	None		Has not exhausted SOC (at least platinum doublet remaining)

Trials and cohorts that are considered ineligible (4 cohorts from 3 trials)

Trial	Cohort	Molecular	Ineligibility reasons
<a href="#">METC 02</a> <a href="#">KAYBAS</a> <a href="#">(Phase 1/2)</a>	Dose expansion - monotherapy - Colorectum	KRAS G12D, PD-L1 >= 50.0	No colorectal cancer
<b>METC 03</b> NO-SEE797ES	Dose escalation - monotherapy	EGFR C797S	C797S in EGFR in canonical transcript
<b>METC 05</b> PICKME3CA	<i>Applies to all cohorts below</i>	None	No PIK3CA activating mutation(s)
	Dose expansion - monotherapy - NSCLC <i>(closed)</i>		
	Dose expansion - monotherapy - Other cancer types <i>(closed)</i>		Tumor belongs to DOID term(s) lung non-small cell carcinoma

Trials and cohorts that are not evaluable or ignored (0 trials)

None